3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Colorectal Neoplasms
220
Rectal Neoplasms
137
Stomach Neoplasms
95
Colonic Neoplasms
87
Pancreatic Neoplasms
82
Esophageal Neoplasms
71
Neoplasm Metastasis
58
Squamous Cell Carcinoma of Head and Neck
43
Head and Neck Neoplasms
42
Adenocarcinoma Of Esophagus
37
Neoplasms
36
Breast Neoplasms
35
Esophageal Squamous Cell Carcinoma
27
Carcinoma, Hepatocellular
22
Cholangiocarcinoma
21
Adenocarcinoma
17
Nasopharyngeal Carcinoma
16
Bile Duct Neoplasms
14
Gallbladder Neoplasms
13
Carcinoma, Squamous Cell
13
Biliary Tract Neoplasms
13
Anus Neoplasms
13
Urinary Bladder Neoplasms
11
Liver Neoplasms
10
Carcinoma
9
Nasopharyngeal Neoplasms
8
Colorectal Cancer Metastatic
8
Peritoneal Neoplasms
7
Recurrence
6
Ovarian Neoplasms
6
Interventions
Cyclophosphamide
3
tumor necrosis factor-alpha, CNGRC fusion protein, human
2
liposomal doxorubicin
2
Paclitaxel
2
Gemcitabine
2
Doxorubicin
2
Dexamethasone
2
Cisplatin
2
Carboplatin
2
Bortezomib
2
vandetanib
1
umbralisib
1
ublituximab
1
regorafenib
1
pomalidomide
1
pembrolizumab
1
nilotinib
1
marizomib
1
lutetium Lu 177 dotatate
1
grapiprant
1
fludarabine phosphate
1
fludarabine
1
durvalumab
1
cemiplimab
1
carotuximab
1
axicabtagene ciloleucel
1
avelumab
1
Thioctic Acid
1
Tamoxifen
1
Receptors, Interleukin-6
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Disease Progression
×
Fluorouracil
×
Clear all
NCT05712356
2026-05-26
BOLSTER
Lisata Therapeutics, Inc.
Phase 2
Terminated
66 enrolled
12 charts